Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
With ANVISA’s commitment for fast review, shouldn’t the Brazil trial be starting very soon?
Come on, let’s have some bid support!!!
Looks thin to a nickel on the ask!
Actually, it’s immunocorrective and showing bigly improved mortality in Philippines! Tidal waves coming inBrazil and India IMHO.
They would be stupid to provide that information in a PR when so many other negotiations are imminent. We should get some news from Brazil soon. ANVISA will turn around the trail application in less than 72 hours, and then the trials will be going. More “problematic” event for you. This will be moving like my VDRM soon!
Thanks! Got PR too today. Hope you had a chance to check out VDRM, nice day today
Nice day today for sure!
Tender offer?
Cool!
Ah, understood now.
May 29. Published today
That Facebook post was MAY 19
Leronlimab is available at the Laban Lung Center in the Phillipines.
https://www.facebook.com/638139345/posts/10159109109154346/?d=n
Nader hasn’t sold stock in many months. You know very well the timeline is false as implied by the article.
This is patently false reporting: https://trialsitenews.com/did-cytodyn-ceo-dump-stock-right-before-fda-publicly-blasted-the-company/
Awesome!!! Send a copy to Tom Fitton at Judicial Watch and to Jay Sekulow at the American Center for Law and Justice (ACLJ).
Over a year ago:
May 27, 2021: 1337 Americans died of COVID.
Stil active in Philippines?
And now, COVID negative people who had the vaccine are showing Rantes according to Bruce Patterson on Twitter. Who will be able to treat that, and who will pay for it?
Sell the news and buy CYDY. Buy low and sell high.
Shortablestocks.com shows CYDY is “zero borrow”
Breaking data-post-vaccination COVID negative patients with symptoms months out from vaccine have elevated pro-inflammatory markers CCL5/RANTES and TNF-a!!
— Bruce K. Patterson MD (@brucep13) May 26, 2021
I’d love to see the Sacklers in Jail.
Nice consolidation!
I’ve been lurking here, looking for signs of a breakout before I jump in. CBD has huge healing potential, I am doing well so far with VDRM and interested in what other Cydy investors think of it.
I’m not going to do wha Elmer Fudd says and vote for hoe and change.. This group needs to bring solid business proposals. One other thing, we are all the same class of shareholder.
Biomm has applied for trial approval from ANVISA, how long does that approval take?
From Jesus on YMB: CD16 (Moderate) and CD17 (Critical)
Vs CD12 (Severe/ Critical)
1. CD12 - Severe - CytoDyn, Dr. Bruce Patterson, Dr. Lalezari, Dr. seethmaraju, wanted 2 doses (1,400MG). The data gathered suggested that Leronlimab fades from the body day 7-10, with its peak being on day 3.
With the most powerful dose at 700MG, it allows the body to see the best results at the start, and then maintain the lower iL-6 and Rantes levels weekly with 350MG.
In order to get 4 doses for 28 days (presumed Homeostasis takes a month) they’re also adding an additional 350mg making it, 700, 350, 350, 350 = 1,800MG.
This likely prevents Cytokine Storm, saves the Hospital oxygen, ventilators, and perhaps prevents Long Haulers because it brings the body back into full homeostasis.
2. Why patients with pneumonia in CD16? The data suggests that’s who needs Leronlimab the most and when it shows it’s efficacy. If you recall, President Estrada’s Pneumonia, he was cleared, crediting Leronlimab via his son.
3. Patients (from my research) that have Pneumonia tend to be linked to Long Haulers. I would not one bit doubt that this data can also drive us to see if it can at least prevent Long Haulers; hence the 60 day study as well. Aka Clinical Status.
CD17 Critical
1. 2,800 MGs was the magic number we all felt we needed and now we got it. 1 week apart. This should help trends go to 86-92% survival improvement.
2. Intravenous = Quicker to the body. Older patients / geriatric patients need a faster response from the Paramedic / nurses and Doctors. Intravenous medication is the same. This helps the age stratification issue that the field will see in critical patients. 1 answer should fit all.
3. Trial size...NP explained 120 patients was all The “Hospital Israelita Albert Einstein” think was need needed based on the efficacy of this drug. To help expedite the P-Value I believe they more than doubled that number to achieve that P-Value via Interim Analysis so all the countries like MHRA, Brazil and maybe Philippines and India if they don’t give it an EUA before the trial ends.
Paraphrased the layout of: Comfortable_fan_8103 from Reddit
“if the trial starts by june 7, given 167 sites, we should get the 120 data by july 21;
now remember, these 120 are critical patients who received 4 serial doses of iv leronlimab.” -MGK
For now, ignore anything that doesn’t come from the company.
The trial is designed to have a statistically significant P-Value of .05 or better.
You might get a better answer from Dr Lakezari
Otavio Berwanger, MD, PhD
Director of the Academic Research Organization (ARO) at Hospital Israelita Albert Einstein
About
Dr Berwanger (MD; PhD) is a cardiologist and clinical trialist who has been working as Chair of the Steering Committee and Global Study Director of large-scale randomized clinical trials and Real World Evidence Studies. He coordinates a network of 167 Cardiovascular Research Sites in 10 countries (Brazil, Autralia, New Zealand, Canada, China, Russia, Ukraine, Argentina, Peru and Colombia). He is currently the Director of the largest clinical trials unit in South America (ARO- Hospital Israelita Albert Einstein) in Sao Paulo-SP, Brazil. He was the main presenter of over 10 clinical trials in late-breaking clinical trial sessions at the American College of Cardiology Scientific Sessions, American Heart Association Scientific Sessions and European Congress of Cardiology-ESC. He has published manuscripts in major medical journals such as JAMA, New England Journal of Medicine, Lancet, Circulation, JACC and the European Heart Journal. Dr Berwanger´s current interests includes the conduct of innovative clinical trial models using Big Data, Artificial Intelligence and Machine Learning Techniques, as well as the use of wearables and devices to obtain patient reported-outcomes.
https://www.clinicaltrials.gov/ct2/show/NCT04901676
Moderate are those not requiring intubation or ECMO
They would look very foolish to ignore it.